eli lilly retatrutide study Lilly's Phase 3 clinical studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments Eli Lilly Will File For

If exposed to high heat, contact the pharmacy before continuing to use the vial

That is the largest weight loss result ever recorded in a late-stage pharmaceutical trial for an obesity drug

If the solution then appears clear, it's likely still usable

Across pivotal Phase 3 trials, mean weight loss has scaled with the number of receptors a compound engages: semaglu tide (single agonist) at 14.9%, tirzepatide (dual agonist) at 22.5%, and retatrutide (triple agonist) at 28.3% over 80 weeks

Still, the benefits and risks of bariatric surgery are well-documented, with proven long-term health improvements

Even some people who have health insurance coverage for obesity drugs say they turn to telehealth and compounding because they couldn't reliably find the brand-name drugs in local pharmacies